Fangya Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fangya Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jianyu Zhang
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
3 shared publications - Feng Guo
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
1 shared publication - Tao Meng
Tianjin University
1 shared publication - Tingting Fang
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
1 shared publication Yinong Qiu
Tianjin University
1 shared publication- Zipeng Zhao
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
1 shared publication
Latest Publications
- 4 December 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 287, 138313
Time-resolved fluorescence studies reveal differences in dynamic motion between main proteases of SARS-CoV-2 and SARS-CoV
- 4 December 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 287, 138313
Time-resolved fluorescence studies reveal differences in dynamic motion between main proteases of SARS-CoV-2 and SARS-CoV
- Open Access
Comprehensive Understanding of the Kinetic Behaviors of Main Protease from SARS-CoV-2 and SARS-CoV: New Data and Comparison to Published Parameters
The main protease (Mpro) is a promising drug target for inhibiting the coronavirus due to its conserved properties and lack of homologous genes in humans. However, previous studies on Mpro’s kinetic parameters have been confusing, hindering the selection of accurate inhibitors. Therefore, obtaining a clear view of Mpro’s kinetic parameters is necessary. In our study, we investigated the kinetic behaviors of Mpro from SARS-CoV-2 and SARS-CoV using both FRET-based cleavage assay and the LC-MS method, respectively. Our findings indicate that the FRET-based cleavage assay could be used for preliminary screening of Mpro inhibitors, while the LC-MS method should be applied to select the effective inhibitors with higher reliability. Furthermore, we constructed the active site mutants (H41A and C145A) and measured the kinetic parameters to gain a deeper understanding of the atomic-level enzyme efficiency reduction compared to the wild type. Overall, our study provides valuable insights for inhibitor screening and design by offering a comprehensive understanding of Mpro’s kinetic behaviors.
Open AccessComprehensive Understanding of the Kinetic Behaviors of Main Protease from SARS-CoV-2 and SARS-CoV: New Data and Comparison to Published Parameters
The main protease (Mpro) is a promising drug target for inhibiting the coronavirus due to its conserved properties and lack of homologous genes in humans. However, previous studies on Mpro’s kinetic parameters have been confusing, hindering the selection of accurate inhibitors. Therefore, obtaining a clear view of Mpro’s kinetic parameters is necessary. In our study, we investigated the kinetic behaviors of Mpro from SARS-CoV-2 and SARS-CoV using both FRET-based cleavage assay and the LC-MS method, respectively. Our findings indicate that the FRET-based cleavage assay could be used for preliminary screening of Mpro inhibitors, while the LC-MS method should be applied to select the effective inhibitors with higher reliability. Furthermore, we constructed the active site mutants (H41A and C145A) and measured the kinetic parameters to gain a deeper understanding of the atomic-level enzyme efficiency reduction compared to the wild type. Overall, our study provides valuable insights for inhibitor screening and design by offering a comprehensive understanding of Mpro’s kinetic behaviors.
- Open Access
- 5 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
How to deal with future possible coronavirus: hints from the analysis of the interaction between potential inhibitors with 3C-Like protease via molecular docking
The COVID-19 pandemic has resulted in millions of infections and deaths. However, there is still a lack of broad-spectrum effective and safe anti-CoV drugs. 3CL protease is one of the promising targets for the development of anti-CoV drugs. In this study, we explored the binding effects of 36 potential inhibitors with five hu-man coronavirus 3CL proteases (SARS-CoV-2, MERS-CoV, SARS-CoV, HCoV-HKU1 and HCoV-229E) via molecular docking using SwissDock. The correlation study demonstrated that small molecule inhibitors with higher molecular weight were likely to be more effective. Based on the fact that SARS-CoV-2 3CLpro had the poorest binding tendency and affinity with ligands, we predicted that the CoVs will become more and more difficult to overcome as they evolve. The interaction analysis showed that the lethal human coronavirus 3CL proteases had higher hydrogen bonding interaction propensity on Glu16X. These findings offer interesting perspectives for future drug design strategies against human coronavirus.
- 5 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessHow to deal with future possible coronavirus: hints from the analysis of the interaction between potential inhibitors with 3C-Like protease via molecular docking
The COVID-19 pandemic has resulted in millions of infections and deaths. However, there is still a lack of broad-spectrum effective and safe anti-CoV drugs. 3CL protease is one of the promising targets for the development of anti-CoV drugs. In this study, we explored the binding effects of 36 potential inhibitors with five hu-man coronavirus 3CL proteases (SARS-CoV-2, MERS-CoV, SARS-CoV, HCoV-HKU1 and HCoV-229E) via molecular docking using SwissDock. The correlation study demonstrated that small molecule inhibitors with higher molecular weight were likely to be more effective. Based on the fact that SARS-CoV-2 3CLpro had the poorest binding tendency and affinity with ligands, we predicted that the CoVs will become more and more difficult to overcome as they evolve. The interaction analysis showed that the lethal human coronavirus 3CL proteases had higher hydrogen bonding interaction propensity on Glu16X. These findings offer interesting perspectives for future drug design strategies against human coronavirus.